Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma

Clinical EndocrinologyVolume 66, Issue 1 p. 149-150 Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma D. McCall, D. McCall Regional Centre for Endocrinology and Diabetes,Search for more papers by this authorS. J. Hunter, S. J. Hunter Regional Centre for Endocrinology and Diabetes,Search for more papers by this authorR. S. Cooke, R. S. Cooke Department of Neurosurgery,Search for more papers by this authorB. Herron, B. Herron Department of Neuropathology andSearch for more papers by this authorB. Sheridan, B. Sheridan Regional Endocrine Laboratory, Royal Victoria Hospital, Belfast, N. Ireland, UKSearch for more papers by this authorA. B. Atkinson, A. B. Atkinson Regional Centre for Endocrinology and Diabetes,Search for more papers by this author D. McCall, D. McCall Regional Centre for Endocrinology and Diabetes,Search for more papers by this authorS. J. Hunter, S. J. Hunter Regional Centre for Endocrinology and Diabetes,Search for more papers by this authorR. S. Cooke, R. S. Cooke Department of Neurosurgery,Search for more papers by this authorB. Herron, B. Herron Department of Neuropathology andSearch for more papers by this authorB. Sheridan, B. Sheridan Regional Endocrine Laboratory, Royal Victoria Hospital, Belfast, N. Ireland, UKSearch for more papers by this authorA. B. Atkinson, A. B. Atkinson Regional Centre for Endocrinology and Diabetes,Search for more papers by this author First published: 20 September 2006 https://doi.org/10.1111/j.1365-2265.2006.02686.xCitations: 3Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Schlechte, J.A. (2003) Clinical practice. Prolactinoma. New England Journal of Medicine, 349, 2035–2041. 2 Delgrange, E., Crabbe, J. & Donckier, J. (1998) Late development of resistance to bromocriptine in a patient with macroprolactinoma. Hormone Research, 49, 250–253. 3 Kaltsas, G.A., Nomikos, P., Kontogeorgos, G., Buchfelder, M. & Grossman, A.B. (2005) Clinical review: diagnosis and management of pituitary carcinomas. Journal of Clinical Endocrinology and Metabolism, 90, 3089–3099. 4 Pernicone, P.J., Scheithauer, B.W., Sebo, T.J., Kovacs, K.T., Horvath, E., Young, W.F. Jr, Lloyd, R.V.Davis, D.H.Guthrie, B.L. & Schoene, W.C. (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer, 79, 804–812. 5 Petrossians, P., De Herder, W., Kwekkeboom, D., Lamberigts, G., Stevenaert, A. & Beckers, A. (2000) Malignant prolactinoma discovered by D2 receptor imaging. Journal of Clinical Endocrinology and Metabolism, 85, 398–401. Citing Literature Volume66, Issue1January 2007Pages 149-150 ReferencesRelatedInformation